- Treat tobacco dependency
- Offer flu vaccination
- Optimise BMI
- Promote exercise and pulmonary rehabilitation (if MRC≥3)
COPD formulary treatment guide
NHS Dumfries and Galloway Formulary choices for COPD treatment
Based on PCRS ‘Keep it Simple’ approach
All patients
COPD with predominant breathlessness
SABA
- Salbutamol Easyhaler (DPI) 200micrograms as needed (£3.31)
- Salbutamol MDI 100micrograms as needed (£1.50)
- Salamol Easibreathe (BA) 100micrograms as needed (£6.30)
Continued breathlessness that limits daily activities
SABA + (LAMA/LABA)
- Spiolto® (tiotropium/olodaterol) Respimat® 2.5/2.5micrograms, Two puffs daily (£32.50)
- Anoro® Ellipta® (umeclidinium 65mcg/vilanterol 22mcg) One puff daily (£32.50)
COPD with exacerbations (=/- breathlessness)
SABA + LAMA/LABA
- Spiolto (tiotropium/olodaterol) Respimat 2.5/2.5micrograms, Two puffs daily (£32.50)
- Anoro® Ellipta® (umeclidinium 65mcg/vilanterol 22mcg) One puff daily (£32.50)
Consider triple inhaled therapy if:
- 2 or more exacerbations in previous year or admission AND
- Eosinophil count ≥ 0.3 x109/l
SABA + LAMA + (LABA + ICS)
- Trimbow® 87/5/9 MDI or Nexthaler ®Two puffs twice daily (£44.50)
- Trelegy® Ellipta® One puff daily (£44.50)
If no response, step down.
COPD with asthma
- Fobumix Easyhaler® (DP) 320/9 One puff bd (£21.50)or 160/4.5 Two puffs bd (£21.50)
- Fostair® 100/6 Nexthaler® Two puffs bd (£29.32) Or Luforbec® 100/6 MDI (£20.52), Bibefco 100/6 MDI (£13.98)
- DuoResp Spiromax® (DP) 320/9 One puff bd (£29.97)
- Relvar® Ellipta® (92mcg fluticasone furoate/22mcg vilanterol) One puff daily (£22.00)
SABA + LAMA + (LABA + ICS)
- Trimbow® 87/5/9 MDI or Nexthaler ®Two puffs twice daily (£44.50)
- Trelegy® Ellipta® One puff daily (£44.50)
If no response, step down
Before changing medication, THINK AND DO*
- Check inhaler technique
- Check Compliance
- Recheck diagnosis
- Smoking status?
- Co-morbidities?
Think about carbon footprint of inhaler choices
Low carbon footprint <35g CO2e per puff Vs High carbon footprint >35gCO2e per puff
If no response, consider referral to a specialist
(After referring to THINK AND DO points above *)
Editorial Information
Last reviewed: 18/09/2024
Next review date: 18/09/2026
Author(s): Dr Emily Kennedy.
Version: 1